

Notification Date: May 23, 2023 Effective Date: July 11, 2023

## KIT Mutation Exons 8-11 and 17, Hematologic Neoplasms, Sequencing, Varies

Test ID: KITE

## **Explanation:**

On the effective date KITE will become obsolete. Please refer to the recommended alternative below.

## **Recommended Alternative Test:**

| Test ID | Test Name  | Genetic Test Information  |
|---------|--|---|
| NGSHM   | MayoComplete Myeloid<br>Neoplasms, Comprehensive<br>OncoHeme Next-Generation<br>Sequencing, Varies | This test includes next-generation sequencing to evaluate for the following 47 genes and select intronic regions: ANKRD26, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KDM6A, KIT, KRAS, MPL, NF1, NPM1, NRAS, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SH2B3, SF3B1, SMC3, SRSF2, STAG2, STAT3, TERT, TET2, TP53, U2AF1, UBA1, WT1, and ZRSR2 |
| NGAML   | MayoComplete Acute Myeloid<br>Leukemia, 11-Gene Panel, Varies                                      | This test includes next-generation sequencing to evaluate for the following 11 genes: CEBPA, DNMT3A, FLT3, IDH1, IDH2, KIT, KRAS, NPM1, NRAS, RUNX1, and TP53.  |

## Questions

Contact Connie Penz, Laboratory Resource Coordinator at 800-533-1710.